Survival and Treatment Outcomes in Patients with Extracranial Oligometastatic Breast Cancer: Single-Center Experience

Survival and Treatment Outcomes in Patients with Extracranial Oligometastatic Breast Cancer: Single-Center Experience

OBJECTIVEOligometastatic tumors are usually characterized by a solitary or small number of metastatic lesionsconfined to a single organ. This study aims to investigate the prognostic factors for overall survival inpatients with extracranial oligometastatic breast cancer and share our own experiences.METHODSWe evaluated 130 patients who were admitted for the diagnosis of extracranial oligometastatic breastcancer at the University of Health Sciences Istanbul Training and Research Hospital Department ofRadiation Oncology between 2013 and 2017.RESULTSAge (p=0.003), type of surgery (p

___

  • 1. Eng LG, Dawood S, Sopik V, Haaland B, Tan PS, Bhoo- Pathy N, et al. Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat 2016;160(1):145–52.
  • 2. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010;102(7):456–63.
  • 3. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol 2018;29:1634–57.
  • 4. Hanrahan EO, Broglio KR, Buzdar AU, Theriault RL, Valero V, Cristofanilli M, et al. Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer 2005;104(6):1158–71.
  • 5. Carmichael AR, Anderson EDC, Chetty U, Dixon JM. Does local surgery have a role in the management of stage IV breast cancer? Eur J Surg Oncol 2003;29:17–9.
  • 6. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER data. Ann Surg Oncol 2007;14:2187–94.
  • 7. Blanchard DK, Bhatia P, Hilsenbeck SG, Elledge RM. Does surgical management of stage IV breast cancer affect outcome?. Breast Cancer Res Treat 2006;100(Suppl 1):118–9.
  • 8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz, LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009;45:228–47.
  • 9. Lau WF, Binns DS, Ware RE, Ramdave S, Cachin F, Pitman AG, et al. Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia. Med J Aust 2005;182(4):172–6.
  • 10. Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). 2016 ASCO pubs. Journal of Clinical Oncology 2016;34:(15_ suppl)1005.
  • 11. Hu Q, Zhong X, Liu X, Xie Y, Hu K, He P, Lu D, et al. Resection of primary lesion for patients with metastatic breast cancer: where are we now? Chin Clin Oncol 2018;7(3):24.
  • 12. Coombe R, Lisy K, Campbell J, Perry G, Prasannan S. Survival outcomes following aggressive treatment of oligometastatic breast cancer: a systematic review protocol. JBI Database System Rev Implement Rep 2017;15(8):2013–9.
  • 13. Xiong Z, Deng G, Huang X, Li X, Xie X, Wang J, et al. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manag Res 2018;10:287–95.
  • 14. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008;68(9):3108–14.
  • 15. van Walsum GA, de Ridder JA, Verhoef C, Bosscha K, van Gulik TM, Hesselink EJ, et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. Eur J Surg Oncol 2012;38(10):910–7.
  • 16. Meimarakis G, Rüttinger D, Stemmler J, Crispin A, Weidenhagen R, Angele M, et al. Prolonged overall survival after pulmonary metastasectomy in patients with breast cancer. Ann Thorac Surg 2013;95(4):1170– 80.
  • 17. Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, et al. Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer 1996;32A(11):1876–87.
  • 18. O`Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10:20–9.
  • 19. Bourgier C, Khodari W, Vataire AL, Pessoa EL, Dunant A, Delaloge S, et al. Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. Radiother Oncol 2010;96(2):199–203.
  • 20. Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N, et al. Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol 2018;126(1):177–80.
  • 21. Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol 2010;33(2):157–63.
  • 22. Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, et al. Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast Cancer 2012;19(3):218–37.
  • 23. Yoo GS, Yu JI, Park W, Huh SJ, Choi DH. Prognostic factors in breast cancer with extracranial oligometastases and the appropriate role of radiation therapy. Radiat Oncol J 2015;33(4):301–9.
  • 24. Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Alexander C. Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol 2012;19:3028–34.
Türk Onkoloji Dergisi-Cover
  • ISSN: 1300-7467
  • Başlangıç: 2015
  • Yayıncı: Ali Cangül
Sayıdaki Diğer Makaleler

Oligometastatic Recurrent Ovarian Cancer Treated Using Stereotactic Body Radiotherapy

Satya NARAYAN, Puneet PAREEK, Tej Prakash SONI, Sweta SONI, Puneet BAGRI

A Different Approach to Intensity Modulated Radiation Therapy Patient QA Measurements about Dosimetric Equipment

Rıdvan ÜNAL, Aysun İNAL, İsmail Hakkı SARPÜN

A Rare Primary Lung Tumor: Pulmonary Epithelioid Hemangioendothelioma and a Literature Review

Ömer ÖZBUDAK, İrem Hicran ÖZBUDAK, Hülya DİROL

A Dosimetric Plan Study to Increase the Dose from 63 Gy to 70 Gy in Early-Stage Glottic Larynx Cancer

Murat OKUTAN, Burak ŞENGÜL, Canan KÖKSAL, Evren Ozan GÖKSEL, Kübra ÖZKAYA TORAMAN, Musa ALTUN, Bayram DEMİR

Uveal Melanoma with Thickness between 4 and 6 mm Treated with two Different Radioisotopes (I125 or Ru106): Single Institution Experience

Jacopo LENKOWICZ, Luca TAGLIAFERRI, Monica Maria PAGLIARA, Bruno FIONDA, Andrea SCUPOLA, Luca BOLDRINI, Carmela Grazia CAPUTO, Valentina LANCELLOTTA, Cesare MARINO, Giulia MIDENA, Luigi AZARIO, Maria Antonietta GAMBACORTA, Vincenzo VALENTINI, Maria Antonietta BLASI

The MIF rs755622 Variant may Increase Susceptibility of Breast Cancer but not Gastrointestinal Cancer in a Turkish Population

Nilgün IŞIKSAÇAN, Mustafa PEHLİVAN, Sacide PEHLİVAN, Ayşe Feyda NURSAL, Meral GÜNALDI, Yasemin OYACI

Cochlear Sparing for Brain Tumor Radiotherapy: A Retrospective Study Comparing Intensity-Modulated Radiotherapy and Volumetric Modulated Arc Therapy

Elif Eda ÖZER, Gülşen Pınar SOYDEMİR GÖÇER

Down-Regulation of Death Receptor-5 in Metastatic Cascade of Triple-Negative Breast Cancer

Mohammad Kamalabadi FARAHANI

Strategies to Prevent Postoperative Nausea and Vomiting

Onur KOYUNCU, Senem URFALI, Sedat HAKİMOĞLU, A. Muhittin TAŞDOĞAN

Impacts of Radiotherapy Fractionation on Outcome in Squamous Cell Head and Neck Cancer (SQC HNC)

Gökhan ÖZYİĞİT, Branislav JEREMIC, Pavol DUBINSKY, Marta JEREMIC